NexGel, Inc (NXGL) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NextGel's Shareholder Update Conference Call. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications for Introductions. Please go ahead. Thank you, Operator. Good afternoon and welcome everyone to NextGel's Shareholder Update Conference Call. I'm joined today by Adam Levy, Chief Executive Officer. Before we begin, I'd like to remind everyone the statements made during today's conference call may be deemed forward-looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform Act of 1995. And actual results may differ materially due to a variety of risks, uncertainties, and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company's business, I refer you to our filings that the SEC filed periodically. The company dispends any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, unless otherwise required by law. With that, it's my pleasure to turn the call over to Mr. Adam Levy. Adam, please go ahead. Thank you, Walter, and thank you, everyone, for joining. On today's call, I will discuss our announcement this morning regarding the closing of our transaction to acquire Cellularity's degenerative wound segment. This is a transformational step forward for our company, marking our evolution into a more scalable, diversified medical technology business, tripling our revenue run rate and immediately contributing to profitability. To close on the transaction, we successfully secured capital on more favorable terms, led by Sequence Life Science, a strategic...